Safety and Efficacy Study of Cilostazol to Treat Vasospastic Angina
Status:
Completed
Trial end date:
2016-01-01
Target enrollment:
Participant gender:
Summary
This study will be conducted in accordance with the local regulation of New Drug Application.
Overall duration of this trial will be 3 years after approval of MFDS.
Each subject will participate around 26 weeks, which include the 24 weeks treatment period
and 2 weeks safety follow up period. Withdrawn subjects due to efficacy after 4 weeks
treatment will participate in 6 weeks in total including 2 weeks safety follow up. Withdrawn
subjects with other reason also have 2 weeks follow up period.